Evidence Level
Lithium Orotate is a form of lithium that has attracted attention for its potential health benefits, particularly in mental health and neurodegenerative conditions. The evidence supporting its effects primarily comes from epidemiological studies rather than direct clinical trials. A 2015 review by Vita et al. highlights the association between lithium levels in drinking water and reduced suicide rates across multiple countries, suggesting a protective role of lithium at low doses (Vita et al., 2015).
Further supporting this, Fajardo et al. (2018) conducted a cross-sectional study examining 234 Texas counties and found that higher trace lithium levels in drinking water were associated with lower age-adjusted Alzheimer's disease mortality rates (p=0.01), indicating a potential neuroprotective effect (Fajardo et al., 2018). Additionally, a Danish nationwide nested case-control study by Kessing et al. (2017) reported that higher long-term lithium exposure in drinking water was linked to a reduced incidence of dementia, with an incidence rate ratio of 0.83 for levels exceeding 15 µg/L (Kessing et al., 2017).
Mechanistically, lithium is known to inhibit GSK-3 beta and induce the production of brain-derived neurotrophic factor (BDNF), both of which are implicated in mood regulation and neuroprotection. However, clinical trials specifically evaluating lithium orotate supplements remain scarce, with most research focusing on prescription lithium carbonate at higher doses. Collectively, these findings underscore the need for further investigation into the therapeutic potential of low-dose lithium, particularly in the context of mental health and neurodegenerative diseases.